FDA Approves Merck's Keytruda in Combination with Carboplatin ...

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus ...

KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult ...

FDA approves pembrolizumab with chemotherapy for endometrial ...

On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, ...

FDA approves pembrolizumab with chemotherapy for unresectable ...

On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy ...

Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval ...

KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult ...

FDA Approves Merck's Keytruda in Combination with Carboplatin ...

Approval of Keytruda combination for patients with primary advanced or recurrent endometrial carcinoma is based on results from the ...

FDA Approves Merck's Keytruda (pembrolizumab) Plus Carboplatin ...

FDA approves Merck's Keytruda (pembrolizumab) plus carboplatin and paclitaxel as treatment for adult patients with primary advanced or recurrent endometrial ...

FDA approves pembrolizumab in combination with chemotherapy ...

On October 30, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) in combination with carboplatin ...

FDA grants regular approval for pembrolizumab in combination with

On August 20, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) in combination with pemetrexed and platinum as ...

FDA Approves Pembrolizumab With Chemotherapy in Advanced ...

The FDA approved pembrolizumab (Keytruda; Merck) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients ...

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

FDA approves pembrolizumab combination for the first-line treatment of cervical cancer ... Food and Drug Administration approved pembrolizumab (Keytruda, Merck) ...

FDA Approves Merck's Keytruda for First-Line Treatment of Pleural ...

The Keytruda regimen was compared against pemetrexed and cisplatin or carboplatin. The FDA accepted Merck's filing in May 2024 and granted in ...

FDA Approves Merck's KEYTRUDA® (pembrolizumab) in ...

FDA Approves KEYTRUDA in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with ...

FDA approves pembrolizumab combination for the first-line ...

On October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, ...

FDA Approves Merck's Keytruda (pembrolizumab) Plus Pemetrexed ...

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or ...

FDA approves pembrolizumab with chemoradiotherapy for FIGO ...

On January 12, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients ...

FDA Approved Merck's KEYTRUDA® (pembrolizumab) Plus ...

Merck announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin ...

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus ...

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced ...

U.S. FDA approves Merck's Keytruda chemo combo for lung cancer

* Merck & Co Inc - Under FDA's accelerated approval regulations, this indication is approved based on tumor response rate and progression-free ...

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable ...

On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as ...

US FDA approves Merck's Keytruda plus carboplatin & paclitaxel to ...

Chemotherapy dose reduction was required in 29% of patients receiving Keytruda in combination with chemotherapy, compared to 23% of patients ...